ArticleOxford medical case reports2025
Adenocarcinoma of Müllerian origin developed 22 years after Salpingo-oophorectomy in a woman with BRCA1 mutation: a thought about modification of chemotherapy dose and peritoneal resection.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late recurrence of ovarian cancer is exceedingly rare. We report a case of adenocarcinoma of Müllerian origin that developed 22 years after hysterectomy and bilateral salpingo-oophorectomy (BSO) for ovarian cancer in an 81-year-old woman with a pathogenic BRCA1 mutation. The patient underwent six cycles of reduced-dose carboplatin and paclitaxel, achieving remission with a dramatic decline in CA-125 levels. Women with BRCA mutations have a significantly increased risk of ovarian/tube/peritoneal cancer. Although risk-reducing BSO effectively decreases the risk of ovarian and fallopian tube cancers, the risk of peritoneal cancer remains substantial. This case not only illustrates the persistent lifetime risk of ovarian/tube/peritoneal cancer despite BSO but also underscores the need for reevaluation of prophylactic surgical strategies, particularly regarding the extent of peritoneal resection, in BRCA mutation carriers. Additionally, this case report demonstrated the efficacy of dose-modified chemotherapy for BRCA-associated cancers. Further research is warranted to refine surgical and therapeutic strategies for patients with BRCA mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.